FDA Approves Upadacitinib for Giant Cell Arteritis in Adults Dr. Kamal Kant Kohli2 May 2025 5:30 AM ISTThe FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for...
USFDA approves AbbVie giant cell arteritis drug Rinvoq in adults Ruchika Sharma30 April 2025 4:30 PM ISTNorth Chicago, Ill.: AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily,...
Upadacitinib Shows Long-Term Success in the Treatment of Atopic Dermatitis, finds study Jacinthlyn Sylvia10 Feb 2025 8:45 PM ISTA recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a Janus kinase (JAK)...
Upadacitinib Outperforms Dupilumab in Treating Atopic Dermatitis: Study Dr Riya Dave4 Jun 2024 8:00 PM ISTResearchers have found that upadacitinib (Rinvoq) was more effective than dupilumab (Dupixent) in treating moderate-to-severe atopic dermatitis in a...
JAK inhibitors show promising efficacy in rheumatoid arthritis treatment Isra Zaman3 Nov 2023 9:30 AM ISTA retrospective multicenter study conducted by Japanese researchers has found that Janus kinase (JAK) inhibitors, a class of drugs used to treat...
Upadacitinib increases risk of herpes zoster, serious infections and skin cancer in RA patients: BMJ Jacinthlyn Sylvia6 Sept 2023 10:00 AM ISTIn a recent study examining the safety of upadacitinib in rheumatoid arthritis (RA) patients, researchers have reported an increased risk of serious...
FDA approves Upadacitinib for Crohn's disease in adults Dr. Kamal Kant Kohli19 May 2023 10:00 AM ISTThe U.S. Food and Drug Administration (FDA) has approved Upadacitinib for treatment of adults with moderately to severely active Crohn's disease...
AbbVie gets positive EMA committee opinion for Upadacitinib to treat adults with moderate to severe Crohn's disease Ruchika Sharma28 Feb 2023 1:30 PM ISTDiscovered and developed by AbbVie scientists, upadacitinib is a selective and reversible Janus Kinase (JAK) inhibitor.
Upadacitinib useful option for managing Atopic dermatitis with concomitant hand eczema Aditi27 Jan 2023 8:00 PM ISTNetherlands: Research published in Contact Dermatitis, has concluded that, in daily practice, Upadacitinib is an effective treatment for Atopic...
Upadacitinib improves symptoms of ulcerative colitis as early as day one of initiation Jacinthlyn Sylvia4 Dec 2022 7:45 PM ISTA new study published in the Journal of Clinical Gastroenterology and Hepatology suggests that from day one, upadacitinib 45 mg once daily (QD)...
Abbvie RINVOQ gets European Commission nod for treatment of Active Non-Radiographic Axial Spondyloarthritis in adults Ruchika Sharma31 July 2022 11:30 AM ISTAbbvie RINVOQ gets European Commission nod for Adults with Active Non-Radiographic Axial Spondyloarthritis
Upadacitinib most effective oral JAK inhibitor for treating atopic dermatitis, study claims Medha Baranwal7 Jun 2022 11:00 AM ISTUSA: Janus kinase (JAK) inhibitors are an effective treatment for atopic dermatitis (AD) patients, according to results from a new systematic review....
